News

Advancements in Cadonilimab for Treating Gastric Cancer

Advancements in Cadonilimab for Treating Gastric Cancer

Introduction to Cadonilimab's Role in Gastric Cancer Treatment

Akeso, Inc. (9926.HK) has made significant strides in the fight against gastric cancer through its innovative drug, cadonilimab. Recently, at a notable medical conference, the Phase II study results of the COMPASSION-25 trial were revealed, highlighting cadonilimab's potential as a neoadjuvant therapy combined with the SOX regimen for patients with resectable gastric adenocarcinoma.

Key Findings from the Phase II COMPASSION-25 Study

The results from this Phase II study are promising. Overall, the pathologic complete response (pCR) rate was calculated at 28.6% across all evaluable patients. Particularly encouraging is the pCR rate among those who followed the cadonilimab Q3W dosing regimen, which reached an impressive 50.0%. This measurement, which indicates no detectable tumor cells in surgical samples post-treatment, is critical for assessing the efficacy of neoadjuvant treatments.

Major Pathologic Response Rate

A significant highlight from the study was the major pathologic response (MPR) rate, which stands at 71.4% for the entire patient cohort. For those treated with the cadonilimab Q3W regimen, the MPR soared to 85.7%. This suggests that a majority of patients experienced substantial regression of their tumors, a vital factor in improving surgical outcomes.

R0 Resection Achievements

One of the remarkable outcomes was that every patient who underwent surgery achieved an R0 resection status. This indicates that all tumors were successfully removed with clear margins, substantially increasing the chances of long-term survival and reducing recurrence risk.

Benefits of Tumor Downstaging

The study also reported that 85.7% of patients achieved downstaging of the primary tumor, with 75.0% also seeing a reduction in lymph node involvement. These results affirm the efficacy of cadonilimab in reducing tumor burden, which is crucial for ensuring that surgical interventions are more effective and safe.

Safety Profile of Cadonilimab

In terms of safety, cadonilimab displayed a manageable safety profile. The adverse effects experienced by patients aligned with those typically seen in patients receiving the SOX regimen and immune checkpoint inhibitors, with no unexpected issues arising.

Significance of Combination Treatment

While chemotherapy has traditionally been the backbone of treatment for advanced gastric cancer, its efficacy is limited. Cadonilimab's dual mechanism—targeting PD-1 and CTLA-4—enhances its anti-tumor effects compared to traditional therapies, helping to overcome resistance mechanisms that tumors may employ against classic treatments.

Commercial Developments and Future Directions

The clinical efficacy of cadonilimab is well-documented, with its combination with chemotherapy already approved for initial treatment of advanced gastric cancer in regions beyond China. Akeso continues to expand its clinical trials, including pivotal studies assessing cadonilimab's ability to provide new options for patients with treatment-resistant gastric cancer.

A Vision for Comprehensive Cancer Care

With its robust pipeline, which features over 50 innovative assets across various disease areas, Akeso aims to lead in biopharmaceutical research and commercialization. By leveraging its expertise and technological advancements, the company seeks to develop effective and accessible therapies for individuals suffering from critical conditions.

Frequently Asked Questions

What is cadonilimab?

Cadonilimab is a first-in-class bispecific antibody that targets PD-1 and CTLA-4, enhancing the immune response against tumors.

What was the purpose of the COMPASSION-25 trial?

The trial aimed to evaluate the efficacy of cadonilimab as neoadjuvant therapy for patients with resectable gastric cancer.

What were the main findings of the study?

The study found a 28.6% pCR rate overall, with a 50% rate for those on the cadonilimab Q3W regimen, indicating potential effectiveness in tumor eradication.

What is the safety profile of cadonilimab?

Cadonilimab showed a manageable safety profile, with adverse events consistent with existing treatments without new safety concerns.

Is cadonilimab approved for use?

Yes, cadonilimab has been approved for use in combination with chemotherapy for advanced gastric cancer in certain markets.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Apani Adds Kelsun Assets to Its Natural Fiber Platform

Updated Category News Views 162

A materials deal with more chemistry than chest-thumping Seaweed and cotton have landed under one roof, which is a lot more interesting than another apparel brand slapping a green label on ordinary fabric. Apani said November 17 it acquired the assets of Keel Labs, bringing Keel's seaweed-based Kelsun fiber alongside Apani's enhanced cotton-cellulose filament technology....

Continue Reading
Snowrise Targets the Blind Spots in CPG Sales Data

Updated Category News Views 35

A sales total can look healthy while the floorboards are quietly rotting underneath it. That is the uncomfortable CPG problem Snowrise is aiming at: brands know what moved last quarter, but often cannot identify which stores, channels, communities, or promotions actually created the result. Plenty of management teams still steer by topline revenue, net distribution gains,...

Continue Reading
illumine Targets Childcare Chain Control and Risk Gaps

Updated Category News Views 10

Expansion Gets Messy Before It Gets Impressive Childcare operators do not usually stumble because they forgot how to care for children; they stumble because the back office fractures as the network grows. One center handles fees one way, another lets enrollment leads work a different funnel, and headquarters discovers too late that its reports are arguing with each other....

Continue Reading
Vuzix Bets on Lightweight Color Glasses for OEM Partners

Updated Category News Views 72

Forty grams is where this story gets interesting, because faces are ruthless product testers. People will tolerate plenty of clever technology right up until it pinches, looks goofy, leaks light, or makes them feel like they are wearing a science project. Vuzix is trying to clear that hurdle with Ultralite Color, a full-color AI eyewear reference platform built for OEM...

Continue Reading
Red Cat Stock Drama: Revenue Targets and Legal Waves

Updated Category News Views 183

Red Cat's Revenue Predictions Crash and Burn Sitting there on August 6, 2026, Red Cat Holdings had everyone believing they were on a fast track to hitting a hefty revenue target: $150–$180 million for FY2026. CEO Jeffrey Thompson didn't mince words, boasting confidence like a captain before a storm. Fast forward three months, and they're waving the white flag, tossing...

Continue Reading
Mantle's Japan Listing Puts $MNT Through a Real Test

Updated Category News Views 117

Japan's crypto gatekeepers just handed Mantle a key, not a crown. The November 18 listing of $MNT on GMO Coin is a meaningful operational win because getting onto a Japanese centralized exchange is not the usual loose-change exercise seen in friendlier jurisdictions. Mantle cleared a review process involving GMO Coin and the Japan Virtual and Crypto Assets Exchange...

Continue Reading
Markel Elevates War Risk Expertise in London Market

Updated Category News Views 73

A Specialty Desk Gets Its Own Weather Vane War and political violence underwriting is not a corner of insurance where a fancy title change can be shrugged off. The ground shifts under the policyholder, the broker and the carrier without much warning, and a bad call can sit on a book for years. Markel Insurance has named Chloe Gordge Director of War and Political Violence...

Continue Reading
Legato Frames Put Tiny AI to a Real-World Hearing Test

Updated Category News Views 231

A hearing aid that never enters the ear is a deceptively brutal product challenge. It has to hear speech through a mess of restaurant clatter, traffic, wind and ordinary human commotion; it has to run all day; and, crucially, it cannot look like a medical concession somebody reluctantly straps on. Legato Frames are aiming right at that knot, with femtoAI providing the...

Continue Reading
MacDill Mold Case Puts Privatized Housing on Notice

Updated Category News Views 194

Four hundred fifty-four people are a hard number to shrug off. The expanded civil case over alleged toxic mold conditions at MacDill Air Force Base now covers 105 military families, up from 39 households when it was filed in September 2025. Their complaint against The Michaels Organization and affiliated entities may be the largest known military-housing lawsuit in the...

Continue Reading
ETCO Targets the Unflashy Weak Link in Battery Storage

Updated Category News Views 16

A battery cabinet can look impressive right up until one lousy connection becomes the problem nobody budgeted for. ETCO Incorporated’s new lineup of standard and custom connectors and terminals goes after that unglamorous part of battery energy storage systems: the physical handoff points carrying power, grounding equipment, and tying auxiliary components together. It...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Future of Generative AI Chipset Market Growth

Updated Category News Views 252

Generative AI Chipset Market Size Analysis The Generative AI Chipset Market is experiencing remarkable growth as the demand for high-performance AI hardware accelerates across various industries. Currently valued at approximately USD 37.29 billion in 2023, the market is anticipated to reach an impressive USD 454.50 billion by 2032, representing a staggering compound...

Continue Reading
CrateDB Welcomes Robert Ekstrom as New Chief Executive Officer

Updated Category News Views 297

CrateDB Welcomes Robert Ekstrom as New Chief Executive Officer CrateDB, the groundbreaking real-time database solution designed for analytics, search, and AI applications, has announced the exciting appointment of Robert Ekstrom as the new Chief Executive Officer. His leadership is viewed as a pivotal moment for the company, propelling its growth strategies and...

Continue Reading
Novartis AGM Highlights: Board Changes and Dividend Increase

Updated Category News Views 463

Key Outcomes from Novartis' Annual General Meeting Today, Novartis held its Annual General Meeting (AGM) where shareholders gathered to discuss and approve various resolutions proposed by the Board of Directors. It was an important day for the company, as a strong turnout highlighted investor engagement and confidence. Dividend Increase for 2024 This year marks a...

Continue Reading
Understanding Alliance Witan PLC's Net Asset Valuation Insights

Updated Category News Views 116

Understanding Alliance Witan PLC's Financial Standing Alliance Witan PLC stands out in the investment landscape, offering its shareholders a detailed look at their Net Asset Value (NAV). As of the latest reporting date, the financial metrics reveal significant information pertaining to the company's performance and shareholder value. Net Asset Value Calculation At the...

Continue Reading
Remembering Jimmy Carter: A Legacy of Service and Humanity

Updated Category News Views 375

Remembering Jimmy Carter: A Legacy of Service and Humanity Habitat for Humanity joins millions around the globe in reflecting on the remarkable life of former U.S. President Jimmy Carter. He is widely recognized not only as a political leader but also as a formidable advocate for affordable housing. A Champion for Affordable Housing Throughout his life, President Carter...

Continue Reading